SEC Form 4 · accession 0000950138-18-000465
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Trudeau
Officer — President and CEO · Director
Period of report
Jul 1, 2018
Accepted (ET)
Jul 3, 2018 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jul 1, 2018 | F | 34,708 | $18.66 | D | 235,253 | D |
Table II — derivative securities
No Table II lines on this filing.
Remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.